2021年6月,第一款国产ADC药物韦迪西妥单抗获批上市,研发该药的荣昌生物一举成为国内ADC的先行者。面对巨大的临床需求和市场前景,恒瑞医药,东曜药业,多禧生物,科伦博泰,云顶新耀等在内的多家国内药企纷纷摩拳擦掌,踊跃布局,ADC药物已然成为继PD-1/PD-L1的下一个研发风口。放眼未来的ADC赛道,国内外药企并驱争先,精彩纷呈,谁能书写下一个传奇,我们拭目以待。参考文献:1. Global Antibody-drug Conjugates (ADCs): Approvals & Clinical Trails Review. https://www.biochempeg.com/article/208.html2. Kang, M. S., Kong, T., Khoo, J., & Loh, T. P. (2021). Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates. Chemical science, 12(41), 13613–13647.3. Baah, S., Laws, M., & Rahman, K. M. (2021). Antibody-Drug Conjugates-A Tutorial Review. Molecules (Basel, Switzerland), 26(10), 2943.4. Bargh, J. D., , Isidro-Llobet, A., , Parker, J. S., , & Spring, D. R., (2019). Cleavable linkers in antibody-drug conjugates. Chemical Society reviews, 48(16), 4361–4374.版权声明/免责声明本文为原创文章,版权归拥有者。仅供感兴趣的个人谨慎参考,非商用,非医用、非投资用。欢迎朋友们批评指正!衷心感谢!文中图片、视频为授权正版作品,或来自微信公共图片库,或取自网络根据CC0协议使用,版权归拥有者。任何问题,请与我们联系(电话:13651980212。微信:27674131。邮箱:contact@drugtimes.cn)。衷心感谢!